Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect.

T Inoue, D J Yang, S Wallace, A Cherif, W Tansey, E E Kim, N Hunter, C G Milross, L Milas, D A Podoloff

Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston 77030, USA.

Anti-cancer drugs 1996 Nov

filter terms:

The aim of this study was to evaluate whether radiolabeled iodoerythronitroimidazole (IETNIM) could predict the radiosensitization effect on tumors. Tumor-bearing mice were irradiated at a dose of 25, 31 and 37 Gy after the injection of IETNIM. They were also exposed to 37 Gy radiation at 35, 70, 140 and 240 min after the i.p. injection of IETNIM. After the irradiation, tumor growth assays were conducted and the effect of IETNIM as a radiosensitizer was estimated as enhancement factor (EF). Tumor uptake was measured at 35, 70, 140 and 240 min after i.p. injection of [131I]IETNIM, which were the same intervals used in the radiosensitization study. EF of IETNIM in mice treated with 25, 30 and 37 Gy irradiation was 0.72, 0.98 and 1.28, respectively. EF of IETNIM in mice irradiated at 35, 70, 140 and 240 min after the injection was 1.50, 1.69, 1.46 and 1.08, which corresponded to the tumor uptake and blood clearance of [131I]IETNIM. [131I]IETNIM may be a suitable radiopharmaceutical to predict the radiosensitization effect of misonidazole analogs on tumors.

Citation

T Inoue, D J Yang, S Wallace, A Cherif, W Tansey, E E Kim, N Hunter, C G Milross, L Milas, D A Podoloff. Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect. Anti-cancer drugs. 1996 Nov;7(8):858-65